{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:30:45Z","timestamp":1789104645210,"version":"build-2803163510"},"reference-count":48,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T00:00:00Z","timestamp":1673913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation (NRF) of Korea","doi-asserted-by":"publisher","award":["NRF-2021R1A2C2011021"],"award-info":[{"award-number":["NRF-2021R1A2C2011021"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation (NRF) of Korea","doi-asserted-by":"publisher","award":["22ZB1160"],"award-info":[{"award-number":["22ZB1160"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003696","name":"Electronics and Telecommunications Research Institute (ETRI)","doi-asserted-by":"publisher","award":["NRF-2021R1A2C2011021"],"award-info":[{"award-number":["NRF-2021R1A2C2011021"]}],"id":[{"id":"10.13039\/501100003696","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003696","name":"Electronics and Telecommunications Research Institute (ETRI)","doi-asserted-by":"publisher","award":["22ZB1160"],"award-info":[{"award-number":["22ZB1160"]}],"id":[{"id":"10.13039\/501100003696","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Chemotherapy-induced peripheral neuropathy (CIPN) is a major drawback in the use of chemotherapeutic agents for patients with cancer. Although studies have investigated a broad number of molecules that might be related to CIPN, the differences in the chemokine pathways between various chemotherapeutic agents, such as vincristine and oxaliplatin, which are some of the most widely used treatments, have not been fully elucidated. We confirmed that the administration (intraperitoneal injections for seven days) of vincristine (0.1 mg\/kg) and oxaliplatin (3 mg\/kg) induced pain by using the von Frey behavioral test. Subsequent applications with vincristine and oxaliplatin led to mechanical allodynia that lasted more than one week from the fifth day. After the induction of mechanical allodynia, the mRNA expression of CXCR2, CXCL1, CXCL3, and CXCL5 was examined in the dorsal root ganglia (DRG) and spinal cord of the CIPN models. As a result, the mRNA expression of CXCR2 robustly increased in the lumbar spinal cord in the oxaliplatin-treated mice. Next, to evaluate the involvement of CXCR2 in CIPN, reparixin, a CXCR1\/2 inhibitor, was administered intrathecally or intraperitoneally with vincristine or oxaliplatin and was further verified by treatment with ruxolitinib, which inhibits Janus kinase 2 downstream of the CXCR1\/2 pathway. Reparixin and ruxolitinib blocked oxaliplatin-induced allodynia but not vincristine-induced allodynia, which suggests that CXCR2-related pathways are associated with the development of oxaliplatin-induced neuropathy. Together with the above results, this suggests that the prevention of oxaliplatin-induced neuropathy by CXCR2 inhibition can lead to successful chemotherapy, and it is important to provide appropriate countermeasures against CIPN development for each specific chemotherapeutic agent.<\/jats:p>","DOI":"10.3390\/ijms24031855","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T01:57:57Z","timestamp":1674007077000},"page":"1855","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prevention of Chemotherapy-Induced Peripheral Neuropathy by Inhibiting C-X-C Motif Chemokine Receptor 2"],"prefix":"10.3390","volume":"24","author":[{"given":"Hee Seong","family":"Cho","sequence":"first","affiliation":[{"name":"Department of Biomedical Science, Graduate School of Biomedical Science and Engineering, Hanyang University, Seongdong-gu, Seoul 04763, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6666-3304","authenticated-orcid":false,"given":"Young In","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science, Graduate School of Biomedical Science and Engineering, Hanyang University, Seongdong-gu, Seoul 04763, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seon Uk","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science, Graduate School of Biomedical Science and Engineering, Hanyang University, Seongdong-gu, Seoul 04763, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Seul","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science, Graduate School of Biomedical Science and Engineering, Hanyang University, Seongdong-gu, Seoul 04763, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Kwon","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, Columbia University, New York, NY 10027, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1051-6495","authenticated-orcid":false,"given":"Sung Jun","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science, Graduate School of Biomedical Science and Engineering, Hanyang University, Seongdong-gu, Seoul 04763, Republic of Korea"},{"name":"Department of Physiology, College of Medicine, Hanyang University, Seongdong-gu, Seoul 04763, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1007\/s00520-021-06042-x","article-title":"Chemotherapy-induced peripheral neuropathy (CIPN): Current therapies and topical treatment option with high-concentration capsaicin","volume":"29","author":"Diel","year":"2021","journal-title":"Support. Care Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2217\/pmt-2018-0020","article-title":"An updated understanding of the mechanisms involved in chemotherapy-induced neuropathy","volume":"8","author":"Hou","year":"2018","journal-title":"Pain Manag."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3322\/caac.21204","article-title":"Chemotherapy-induced peripheral neurotoxicity: A critical analysis","volume":"63","author":"Park","year":"2013","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00280-012-2047-z","article-title":"Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine","volume":"71","author":"Cata","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1529-8027.2008.00156.x","article-title":"Chemotherapy-induced neuropathy","volume":"13","author":"Windebank","year":"2008","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s43440-020-00109-y","article-title":"Chemotherapy-induced peripheral neuropathy: Part 1\u2014Current state of knowledge and perspectives for pharmacotherapy","volume":"72","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jpain.2019.06.008","article-title":"Inflammatory and neuropathic gene expression signatures of chemotherapy-induced neuropathy induced by vincristine, cisplatin, and oxaliplatin in C57BL\/6J mice","volume":"21","author":"Starobova","year":"2020","journal-title":"J. Pain"},{"key":"ref_8","first-page":"13","article-title":"Pharmacological Approaches and Natural Products for Prevention of Chemotherapy-Induced Peripheral Neuropathy-A Review","volume":"12","author":"Cascella","year":"2017","journal-title":"Assessment"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1039\/C8DT00838H","article-title":"The side effects of platinum-based chemotherapy drugs: A review for chemists","volume":"47","author":"Oun","year":"2018","journal-title":"Dalton Trans."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"Boni","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/onc.2009.356","article-title":"Immunogenic death of colon cancer cells treated with oxaliplatin","volume":"29","author":"Tesniere","year":"2010","journal-title":"Oncogene"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1200\/JCO.2002.12.032","article-title":"Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: Report of a clinical trial for patients with esophageal cancer","volume":"20","author":"Khushalani","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1200\/JCO.2003.02.505","article-title":"Phase I\/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer","volume":"21","author":"Grabenbauer","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/mus.20340","article-title":"Oxaliplatin-induced neurotoxicity and the development of neuropathy","volume":"32","author":"Krishnan","year":"2005","journal-title":"Muscle Nerve Off. J. Am. Assoc. Electrodiagn. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/blood.V21.5.640.640","article-title":"Clinical studies with vincristine","volume":"21","author":"Carbone","year":"1963","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"733","DOI":"10.7326\/0003-4819-80-6-733","article-title":"Vincristine neurotoxicity","volume":"80","author":"Rosenthal","year":"1974","journal-title":"Ann. Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJM197407182910305","article-title":"Neurotoxicity of commonly used antineoplastic agents","volume":"291","author":"Weiss","year":"1974","journal-title":"N. Engl. J. Med."},{"key":"ref_18","first-page":"613","article-title":"Vincristine in the treatment of lymphomas and leukemias","volume":"23","author":"Bohannon","year":"1963","journal-title":"Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Brandolini, L., d\u2019Angelo, M., Antonosante, A., Cimini, A., and Allegretti, M. (2019). Chemokine signaling in chemotherapy-induced neuropathic pain. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20122904"},{"key":"ref_20","first-page":"72","article-title":"Chemotherapy-induced polyneuropathy. Part I. Pathophysiology [Polish version: Polineuropatia wywo\u0142ana chemioterapi\u0105. Cz\u0119\u015b\u0107 I. Patofizjologia p. 79]","volume":"16","year":"2012","journal-title":"Contemp. Oncol. Wsp\u00f3\u0142czesna Onkol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"20151","DOI":"10.1073\/pnas.0709250104","article-title":"Chemokines and the pathophysiology of neuropathic pain","volume":"104","author":"White","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1152\/physrev.00011.2002","article-title":"Beyond neurons: Evidence that immune and glial cells contribute to pathological pain states","volume":"82","author":"Watkins","year":"2002","journal-title":"Physiol. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pharmthera.2010.01.002","article-title":"Chemokines, neuronal\u2013glial interactions, and central processing of neuropathic pain","volume":"126","author":"Gao","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.neuropharm.2018.03.004","article-title":"Levo-corydalmine alleviates vincristine-induced neuropathic pain in mice by inhibiting an NF-kappa B-dependent CXCL1\/CXCR2 signaling pathway","volume":"135","author":"Zhou","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12974-018-1116-6","article-title":"A novel interaction between CX3CR1 and CCR2 signalling in monocytes constitutes an underlying mechanism for persistent vincristine-induced pain","volume":"15","author":"Montague","year":"2018","journal-title":"J. Neuroinflammation"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1097\/j.pain.0000000000001212","article-title":"Chemokine CCL2 and its receptor CCR2 in the dorsal root ganglion contribute to oxaliplatin-induced mechanical hypersensitivity","volume":"159","author":"Illias","year":"2018","journal-title":"Pain"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"11729","DOI":"10.1038\/s41598-019-48231-z","article-title":"DF2726A, a new IL-8 signalling inhibitor, is able to counteract chemotherapy-induced neuropathic pain","volume":"9","author":"Brandolini","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3521746","DOI":"10.1155\/2019\/3521746","article-title":"Investigation of key genes and pathways in inhibition of oxycodone on vincristine-induced microglia activation by using bioinformatics analysis","volume":"2019","author":"Liu","year":"2019","journal-title":"Dis. Markers"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"110003","DOI":"10.1016\/j.biopha.2020.110003","article-title":"Mitoquinone alleviates vincristine-induced neuropathic pain through inhibiting oxidative stress and apoptosis via the improvement of mitochondrial dysfunction","volume":"125","author":"Chen","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1172\/JCI71389","article-title":"Monocytes expressing CX3CR1 orchestrate the development of vincristine-induced pain","volume":"124","author":"Old","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Makker, P.G., Duffy, S.S., Lees, J.G., Perera, C.J., Tonkin, R.S., Butovsky, O., Park, S.B., Goldstein, D., and Moalem-Taylor, G. (2017). Characterisation of immune and neuroinflammatory changes associated with chemotherapy-induced peripheral neuropathy. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0170814"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"110805","DOI":"10.1016\/j.biopha.2020.110805","article-title":"Hair follicle bulge-derived stem cells promote tissue regeneration during skin expansion","volume":"132","author":"Cheng","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s002800050396","article-title":"Vincristine-induced dermal toxicity is significantly reduced when the drug is given in liposomes","volume":"37","author":"Boman","year":"1996","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"43375","DOI":"10.18632\/oncotarget.6234","article-title":"Targeting CXCR1 on breast cancer stem cells: Signaling pathways and clinical application modelling","volume":"6","author":"Brandolini","year":"2015","journal-title":"Oncotarget"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"23426","DOI":"10.18632\/oncotarget.25193","article-title":"Oxaliplatin-induced blood brain barrier loosening: A new point of view on chemotherapy-induced neurotoxicity","volume":"9","author":"Branca","year":"2018","journal-title":"Oncotarget"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.bbcan.2019.01.005","article-title":"Potential roles and targeted therapy of the CXCLs\/CXCR2 axis in cancer and inflammatory diseases","volume":"1871","author":"Cheng","year":"2019","journal-title":"Biochim. Et Biophys. Acta (BBA)-Rev. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.nbd.2016.02.007","article-title":"The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model","volume":"92","author":"Haile","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.pain.2010.10.030","article-title":"Intraepidermal nerve fiber loss corresponds to the development of taxol-induced hyperalgesia and can be prevented by treatment with minocycline","volume":"152","author":"Xin","year":"2011","journal-title":"PAIN\u00ae"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e5097","DOI":"10.7717\/peerj.5097","article-title":"Novel inflammatory cell infiltration scoring system to investigate healthy and footrot affected ovine interdigital skin","volume":"6","author":"Agbaje","year":"2018","journal-title":"PeerJ"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1526-4637.2010.00913.x","article-title":"Role of neuropeptide, cytokine, and growth factor signaling in complex regional pain syndrome","volume":"11","author":"Kingery","year":"2010","journal-title":"Pain Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.neulet.2016.10.004","article-title":"Spinal CXCL5 contributes to nerve injury-induced neuropathic pain via modulating GSK-3\u03b2 phosphorylation and activity in rats","volume":"634","author":"Xu","year":"2016","journal-title":"Neurosci. Lett."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1016\/j.pain.2013.07.002","article-title":"Chemokine contribution to neuropathic pain: Respective induction of CXCL1 and CXCR2 in spinal cord astrocytes and neurons","volume":"154","author":"Zhang","year":"2013","journal-title":"PAIN\u00ae"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/etm.2022.11523","article-title":"Resveratrol ameliorates oxaliplatin-induced neuropathic pain via anti-inflammatory effects in rats","volume":"24","author":"Dong","year":"2022","journal-title":"Exp. Ther. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e20201452","DOI":"10.1084\/jem.20201452","article-title":"Vincristine-induced peripheral neuropathy is driven by canonical NLRP3 activation and IL-1\u03b2 release","volume":"218","author":"Starobova","year":"2021","journal-title":"J. Exp. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0304-3940(80)90077-4","article-title":"Vincristine reduces damage of the blood-brain barrier induced by high intravascular pressure","volume":"17","author":"Larsson","year":"1980","journal-title":"Neurosci. Lett."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1038\/sj.onc.1208442","article-title":"KSHV-GPCR and CXCR2 transforming capacity and angiogenic responses are mediated through a JAK2-STAT3-dependent pathway","volume":"24","author":"Burger","year":"2005","journal-title":"Oncogene"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1744-8069-10-26","article-title":"A simplified up-down method (SUDO) for measuring mechanical nociception in rodents using von Frey filaments","volume":"10","author":"Bonin","year":"2014","journal-title":"Mol. Pain"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0165-0270(94)90144-9","article-title":"Quantitative assessment of tactile allodynia in the rat paw","volume":"53","author":"Chaplan","year":"1994","journal-title":"J. Neurosci. Methods"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/3\/1855\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:08:35Z","timestamp":1760119715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/3\/1855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,17]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["ijms24031855"],"URL":"https:\/\/doi.org\/10.3390\/ijms24031855","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,17]]}}}